ALK alteration is a frequent event in aggressive breast cancers

Breast Cancer Research

Table 2 Correlation of ALK IHC with clinicopathologic parameters in breast cancer

	Total		ALK present		ALK absent		P value
	N	%	N	%	N	%	P value
Total number of cases	972		350	36.0	622	64.0
Age groups
<50	663	68.2	250	37.7	413	62.3	0.1044
≥50	309	31.8	100	32.4	209	67.6
Lymph nodes
N0	300	32.9	108	36.0	192	64.0	0.5832
N1	294	32.3	105	35.7	189	64.3
N2	192	21.1	69	35.9	123	64.1
N3	125	13.7	53	42.4	72	57.6
Metastasis
M0	785	90.1	292	37.2	493	62.8	0.8336
M1	86	9.9	31	36.0	55	64.0
Tumor stage
I	75	8.9	20	26.7	55	73.3	0.0829
II	372	44.1	135	36.3	237	63.7
III	311	36.8	130	41.8	181	58.2
IV	86	10.2	31	36.0	55	64.0
Histologic grade
Well differentiated	74	7.7	21	28.4	53	71.6	0.0039
Moderately differentiated	493	51.2	159	32.2	334	67.8
Poorly differentiated	395	41.1	156	42.0	229	58.0
Histology
Infiltrating ductal carcinoma	890	94.4	329	37.0	561	63.0	0.0076
Infiltrating lobular	40	4.2	7	17.5	33	82.5
Mucinous	13	1.4	2	15.4	11	84.6
Recurrence
Yes	256	29.8	104	40.6	152	59.4	0.1225
No	602	70.2	211	35.1	391	64.9
ER
Negative	333	34.3	150	45.1	183	54.9	<0.0001
Positive	638	65.7	200	31.3	438	68.7
PR
Negative	412	42.5	178	43.2	234	56.8	0.0001
Positive	558	57.5	172	30.8	386	69.2
Triple-negative
Yes	147	15.2	69	46.9	78	53.1	0.0034
No	822	84.8	281	34.2	541	65.8
HER2 FISH
Amplified	275	29.0	108	39.3	167	60.7	0.2647
Normal/gain	672	71.0	238	35.4	434	64.6
ALK FISH
Amplified	126	13.3	61	48.4	65	51.6	0.0031
Normal/gain	821	86.7	284	34.6	537	65.4
Ki-67 IHC
High	818	85.8	318	38.9	500	61.1	0.0001
Low	135	14.2	30	22.2	105	77.8
p-AKT
Positive	212	22.6	132	62.3	80	37.7	<0.0001
Negative	725	77.4	211	29.1	514	70.9
Molecular subtype
HR+Her2-	460	47.4	142	30.9	318	69.1	0.0018
HR+Her2+	232	23.9	83	35.8	149	64.2
TNBC	147	15.1	69	46.9	78	53.1
HR-Her2+	132	13.6	56	42.4	76	57.6
Survival
OS 5 years				77.0		82.4	0.1212

ALK anaplastic lymphoma kinase, IHC immunohistochemistry, ER estrogen receptor, PR progesterone receptor, HER2 human epidermal growth factor receptor 2, FISH fluorescence in situ hybridization, TNBC triple-negative breast cancer, HR hormone receptor, OS overall survival
*Data was not available (NA) for some cases: Age (NA = 19), Lymph nodes (NA = 74), Metastasis (NA = 101), Stage (NA = 145), Grade (NA = 50), Histology (NA = 29), ER (NA = 1), PR (NA = 2), Triple-negative (NA = 3), HER2 FISH (NA = 25), ALK FISH (NA = 24), Ki-67 (NA = 19), and p-AKT (NA = 35)

ISSN: 1465-542X